Biosimilars

• Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases
• Biosimilars – What IBD Patients Should Know
• Biosimilar Patient and Prescriber Outreach Materials
• Biosimilar Development, Review, and Approval
• Biosimilars Basics infographic for Patients
• What is a Biosimilar?
• Prescribing Biosimilar Products
• Biosimilar Development Process

Cirrhosis

• How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study
• Cirrhosis
• Hepatic Encephalopathy

Eosinophilic Esophagitis (EoE)

 

• AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
• Disease Burden and Unmet Need in Eosinophilic Esophagitis
• Biologics in Eosinophilic Gastrointestinal Diseases
• Pathophysiology of Eosinophilic Esophagitis
• Environmental Factors and Eosinophilic Esophagitis
• International Consensus Diagnostic Criteria for Eosinophilic Esophagitis
• Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis
• Treatment of Eosinophilic Esophagitis: Clinical Decision Support Tool
• Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis in Adolescents and Adults: Results From a Phase 3, Randomized, Placebo-Controlled Trial

Hepatitis C Virus (HCV)

• AGA Hepatitis C Virus FAQs
• AGA GI Patient Center: Hepatitis C (HCV)
• HCV Next
• Direct-Acting Antivirals: Side Effects Management Handouts
• CDC Hepatitis C Resource Center
• Patient-Reported Outcomes for Patients With Chronic Liver Disease
• U.S. Department of Veterans Affairs: Hepatitis C Resources for Healthcare Professionals and Patients
• Direct-Acting Antivirals: Side Effects Management Handouts
• Hepatitis C Guidance 2019 Update: AASLD‐IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Hepatitis B Virus (HBV)

 

• CDC Patient Education Center: Hepatitis B Virus
• CDC Testing Asian Americans and Pacific Islanders for Hepatitis
• Q&A: HIV links to diminished control of HBV coinfection
• CDC Interpretation of Hepatitis B Serologic Test Results
• CDC Hepatitis B Resource Center

Inflammatory Bowel Disease (IBD)

• Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
• Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?
• AGA IBD Patient Resources
• Resources For Nurses & Advanced Practice Providers: Crohn’s and Colitis Foundation
• Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?
• Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
• Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers
• STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
• AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease
• Symptoms & Causes of Ulcerative Colitis – NIH Patient Information
• Ostomy Tips and Tricks
• United Ostomy Associations of America, Inc. Colostomy facts
• Crohn’s & Colitis Foundation. Free educational brochures
• Modulation of sphingosine-1-phosphate in ulcerative colitis
• Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
• Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
• A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review
• Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn’s Disease and Ulcerative Colitis
• Shared Decision Making in Gastroenterology:Challenges and Opportunities
• Treatment Approaches in IBD: Shared Decision-Making
• Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19
• Coronavirus and IBD Reporting Database
• An Overview of Novel and Emerging Therapies for Inflammatory Bowel Disease
• Understanding IBD Medications and Side Effects (Patient Handout)
• Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
• Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances
• Emotional Well-being Questionnaire – A Patient/Provider Communication Aid
• Which IBD Medication is Right for Me?
• Vedolizumab Prescribing Information
• IBD Checklist for Monitoring & Prevention
• IBD Checklist for Care Continuity
• Ostomates Food Reference Chart
• Ostomy Resources
• ACG Clinical Guideline – Ulcerative colitis in Adults
• The Development of Patient-Reported Outcome Measures in Inflammatory Bowel Disease
• Emerging Therapies for Inflammatory Bowel Disease
• ACG Clinical Guideline: Management of Crohn’s Disease in Adults
• AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
• Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
• Emerging therapies for the treatment of ulcerative colitis
• A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review

Lysosomal Acid Lipase Deficiency (LAL-D)

 

• Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group
• Lysosomal Acid Lipase Deficiency (LALD) – Patient Information

Non-Alcoholic Fatty Liver Disease (NAFLD)

• Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic
• Review of Clinical Guidelines in the Diagnosis of Pediatric Nonalcoholic Fatty Liver Disease
• The diagnosis and management of nonalcoholic fatty liver disease: A patient‐friendly summary of the 2018 AASLD guidelines
• NAFLD: Differential Diagnosis – Summary
• NIH Genetic and Rare Diseases Information Center: Lysosomal acid lipase deficiency
• The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the AASLD